No­var­tis, BeiGene's PD-(L)1 play takes home an­oth­er win in late-stage da­ta, adding some heft to its mar­ket po­ten­tial

Con­tin­u­ing its quest to shake up the PD-1 mar­ket, BeiGene re­vealed more da­ta Fri­day for its check­point in­hibitor tislelizum­ab, this time in re­cur­rent or metasta­t­ic na­sopha­ryn­geal can­cer.

Re­veal­ing in­ter­im topline re­sults from a Phase III study, BeiGene said the drug met its pri­ma­ry end­point of pro­gres­sion-free sur­vival in the first-line set­ting, com­bined with chemother­a­py. The drug topped chemother­a­py alone at a sta­tis­ti­cal­ly sig­nif­i­cant rate, BeiGene said, po­ten­tial­ly set­ting up a Chi­nese ap­proval in the in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER